R&D and innovation

Normon’s commitment to research and innovation is the foundation on which the company's business strategy is built, enabling it to offer products and services that meet our patient’s highest expectations (and those of our society in general).

The leaders to promote research

At the beginning of the 70's, the company began a stage in which the constant search for innovation is reflected in the establishment of relationships with institutions such as the Spanish National Research Council (CSIC), hospitals and universities, developing a number of research plans.

This profile led Normon to be the first company to develop the first generic drugs in Spain in the 90’s.

Normon is certified with the Good Laboratory Practices (GLP) certificate,

Compliance with BPL, in accordance with Directive 2004/9 / EC, and according to the Royal Decree 822/1993 of May 28, Royal Decree 2043/1994 of October 14, Order 14-4-2000 and Royal Decree 1369/2000 of 19 July, as established by the European Union and the OECD, applicable to the development of new products, ensures the quality and veracity of the studies carried out.